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BACKGROUND: The debate continues regarding the best management for women with low-grade abnormal cervical cytology attending
colposcopy. We compared psychosocial outcomes of alternative management policies in these women.
METHODS: In all, 989 women, aged 20–59 years, with low-grade abnormal cytology, were randomised to immediate large loop excision
(LLETZ) or two to four targeted punch biopsies taken immediately with recall for LLETZ if these showed cervical intra-epithelial
neoplasia 2/3. At 6 weeks after the last procedure, women completed the hospital anxiety and depression scale (HADS) and the impact
of event scale (IES). At 12, 18, 24 and 30 months post recruitment, women completed the HADS and process outcome specific
measure (POSM). Prevalence of significant depression (X8), significant anxiety (X11) and distress (X9) and median POSM scores
were compared between arms. Multivariate odds ratios (ORs) for immediate LLETZ vs biopsy and recall were computed.
RESULTS: Over the entire follow-up, there was no significant difference between arms in cumulative prevalence or risk of significant
depression (OR¼0.78, 95% CI 0.52–1.17) or significant anxiety (OR¼0.83, 95% CI 0.57–1.19). At 6 weeks post procedure, distress
did not differ significantly between arms. At later time points, 8–11% had significant depression and 14–16% had significant anxiety but
with no differences between arms. The POSM scores did not differ between the arms.
CONCLUSIONS: There is no difference in long- or short-term psychosocial outcomes of immediate LLETZ and punch biopsies
with selective recall.
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subsequent follow-up investigations and treatment, can have adverse
psychosocial consequences for women (Bell et al, 1995; Maissi et al,
2004; Gray et al, 2006). For instance, women with low-grade abnormal
cytology are increasingly referred for a colposcopy examination
(TOMBOLA Group, 2006), an event which is associated with
considerable procedural distress (Posner and Vessey, 1988). Several
studies have shown that women have raised anxiety levels before and
during colposcopy (see e.g., Galaal et al, 2007; Hellsten et al, 2007;
Tahseen and Reid, 2008). Less is known about psychosocial outcomes
among women in the months and years after colposcopy.
The most effective management of women with low-grade
abnormal cytology who have a visible abnormality at colposcopy
is controversial. Although immediate treatment by large loop
excision (LLETZ; ‘see-and-treat’) removes all grades of cervical
intra-epithelial neoplasia (CIN), enables full histological examina-
tion, and minimises the possibility of default from follow-up, it can
result in overtreatment (Holschneider et al, 1999; Cardenas-
Turanzas et al, 2005; van Hamont et al, 2006). In addition, LLETZ
has been associated with subsequent raised risk of pre-term
delivery (Noehr et al, 2009). On the other hand, targeted punch
biopsies with selective recall for treatment of those with
histologically confirmed high-grade disease may miss prevalent
CIN and place women with untreated CIN1 at risk of subsequently
developing high-grade lesions (Cox et al, 2003; Byrom et al, 2006).
So far, there has been little consideration of the psychosocial
sequelae of these management strategies. The single available
observational study found that, at 7 days post colposcopy, women
with a colposcopic impression of high-grade disease who had been
managed by immediate LLETZ reported lower anxiety and higher
relief and perception of control than those managed by biopsy and
selective recall (Orbell et al, 2004; Balasubramani et al, 2007).
The United Kingdom TOMBOLA trial was the first randomised
controlled trial to evaluate immediate LLETZ vs targeted punch
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sbiopsies with selected recall in women with low-grade cervical
cytology (Cotton et al, 2006). We found that detection rates
of CIN2 or more severe disease over 3 years did not differ
significantly between the policies (TOMBOLA Group, 2009a). In
this study, we compare the psychosocial impact on women over a
30-month period following the management interventions.
SUBJECTS AND METHODS
Subjects and recruitment
Subject eligibility and recruitment processes are described in detail
elsewhere (Cotton et al, 2006; TOMBOLA Group, 2009b). Briefly,
all participants had been called for a routine cytology test as part of
the NHS Cervical Screening Programmes, and attended for that
test during October 1999 to October 2002. Eligible women were
aged 20–59 years, had low-grade changes (mild dyskaryosis
or borderline nuclear abnormalities (BNA)), were not pregnant
and had no previous cervical treatment. Women were invited to
hospital-based recruitment clinics where they were recruited by
non-clinical staff. Consenting women provided a sample which was
tested for high-risk HPV types; neither the specific purpose of the
sample nor the test result was disclosed to women or clinicians
involved in their management. Women were subsequently
randomised to cytological surveillance or initial colposcopy using
a telephone service provided by Aberdeen University. Those
allocated to colposcopy were sent an appointment to attend a
hospital-based colposcopy clinic.
Procedures and follow-up
During the colposcopy appointment, but before the colposcopic
examination itself, consenting women were randomised to biopsy
and selective recall or immediate LLETZ. Randomisation was
stratified by centre, age group, cytology grade and high-risk HPV
status. When the examination was undertaken, the colposcopist
was aware of the arm to which the woman was allocated. Of women
with adequate colposcopy, those with an abnormal transformation
zone received the intervention assigned by randomisation, whereas
those whose transformation zone was normal were followed-up by
12-monthly cervical cytology tests in primary care. Women with
inadequate colposcopy were excluded from the comparison of the
management policies and were treated according to local NHS
protocols.
For biopsy and selective recall, up to four targeted punch
biopsies were taken from the most abnormal areas. Women with
CIN2/3 on histology were recalled for treatment by LLETZ.
Women with no CIN or CIN1 on histology did not receive any
further treatment at this time and were followed-up in primary
care by 6-monthly cytology tests. In the other arm, the whole
transformation zone, including the abnormality, was removed
immediately by LLETZ. Follow-up after punch biopsies or loop
excision was by cytology tests in primary care every 6 months
(Cotton et al, 2006). Cytology follow-up results were monitored
with subsequent action (next recommended test date or colpo-
scopy referral) based on these results. If women were referred for
colposcopy during the follow-up, they attended local NHS
colposcopy clinics and were treated, if required, according to the
local protocols. Approximately 3 years following recruitment,
women were invited for an exit colposcopy examination.
Psychosocial assessments
Women recruited to TOMBOLA from February 2001 onwards, who
underwent colposcopy during or after December 2001, and who
consented to the second randomisation (n¼989) were asked
to complete seven psychosocial assessments (A1–A7; Figure 1).
These assessments required the completion of psychosocial
questionnaires at recruitment (A1), during the colposcopy
appointment (before the examination and the second randomisa-
tion (A2)), 6 weeks after colposcopy and related interventions
(A3), and at 12 (A4), 18 (A5), 24 (A6) and 30 months (A7) after
recruitment. The recruitment and pre-colposcopy assessments
(A1 and A2) provided data on potential explanatory variables/
confounders. Outcome information was obtained from the assess-
ments undertaken after the second randomisation (A3–A7). The
6-week assessment was designed to evaluate short-term psycho-
social effects after the completion of treatment. The timing of the
assessments of long-term effects (12, 18, 24 and 30 months) was
designed not to be close to the expected follow-up visits (cytology
tests or colposcopy), thus avoiding detecting ‘spikes’ of anxiety
associated with these.
The main outcomes were depression and anxiety over the long-
term as assessed by the hospital anxiety and depression scale
(HADS; Zigmond and Snaith, 1983), with secondary outcomes
assessed using the process outcome specific measure (POSM; Gray
et al, 2005) and the impact of event scale (IES; Horowitz et al,
1979). The HADS was originally designed to screen for clinically
significant anxiety and depression in hospital outpatient clinics,
but has subsequently been validated in primary care and
community settings (Snaith, 2003). It discriminates well between
groups with different prevalence of anxiety and depressive
disorders and is responsive to temporal changes (Herrmann,
1997; Bjelland et al, 2002). Women completed the HADS at all
Baseline assessments Outcome assessments
A1
Recruitment
Pre-colposcopy and
randomisation
6 Weeks
post
procedure
1
12 Months
post 
recruitment
18 Months
post
recruitment
24 Months
post
recruitment
30 Months
post
recruitment
36 Months
post
recruitment
Socio-demographic
questionnaire;
MHLCS; HADS;
POSM
HADS;
EPQ; STAI
2
HADS; IES HADS;
POSM
HADS;
POSM
HADS;
POSM
Colposcopy,
with
treatment if
required
A7 A6 A5 A4 A3 A2
HADS;
POSM
Figure 1 Timing of events and psychosocial assessments, and instruments included. EPQ, Eysenck personality questionnaire; HADS, hospital anxiety
and depression scale; IES, impact of event scale; MHLCS, multi-dimensional health locus of control scale; POSM, process outcome specific measure,
STAI, Spielberger state–trait anxiety inventory.
1At 6 weeks after colposcopy, punch biopsy(ies) or LLETZ, whichever took place last. For women with a
normal transformation zone at colposcopy, those who had immediate loop excision, and those who had punch biopsies which showed CIN0/1, this was
6 weeks after the initial (and only) colposcopy; for those women who had punch biopsies which showed CIN2/3 and were recalled for LLETZ, this was
6 weeks after the treatment appointment.
2All administered at colposcopy appointment, before examination and randomisation.
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sseven time points. As the HADS may fail to detect subtle, but
important, psychosocial consequences of receiving an abnormal
cytology test and its subsequent management, women were also
asked to complete the POSM at the A4–A7 time points. This
instrument was specially developed for use in TOMBOLA.
It includes 16 questions addressing a range of issues, including
cancer, health, fertility and sexual concerns, and has acceptable
psychometric properties (Gray et al, 2005). The IES measures
stress reactions after a specific traumatic event, and has
been validated and used in a variety of contexts (Sundin and
Horowitz, 2002, 2003). It assesses overall distress and, in subscales,
intrusive experiences and avoidance of thoughts or images
associated with the event. The IES was included in the 6-week
questionnaire (A3).
The recruitment questionnaire (A1) included a section on socio-
demographic and lifestyle factors (such as, educational level,
employment status, parity and smoking) and the multi-dimen-
sional health locus of control scale (MHLCS), which measures
three dimensions of health locus of control (chance, internal and
powerful others; Wallston et al, 1978). The pre-colposcopy
questionnaire (A2) included the short form of the Spielberger
state–trait anxiety inventory, which measures anticipatory anxiety
(Marteau and Bekker, 1992), and Eysenck’s short questionnaire,
which measures two dimensions of personality (extraversion–
introversion, neuroticism–stability; EPQ; Eysenck, 1958).
Statistical analysis
All analyses were by intention-to-treat. Questionnaire response
rates were based on the total number of women randomised in
each arm and are thus conservative. The HADS, POSM and IES
scores were not normally distributed. For HADS and IES,
therefore, individuals were defined as ‘cases’ or ‘non-cases’,
depending on whether they scored above or below specific values
on each subscale/instrument. In the primary analysis, ‘significant
depression’ was defined as a HADS depression subscale score X8.
This cut-off has been recommended in guidelines for detecting
depression in cancer patients (Rodin et al, 2006) and used in
previous research among women with abnormal cervical cytology
(Bell et al, 1995). Following Zigmond and Snaith (1983),
‘significant anxiety’ was defined as a HADS anxiety subscale score
X11. Women with a total IES score of X9 were classified as
distressed, with subcategories of mild (total score 9–25), moderate
(26–43) and severe (X44). Following common practise (Salvesen
et al, 1997; Broen et al, 2005), women scoring X20 on the
avoidance or intrusion subscales of the IES were defined as cases.
The total POSM score was computed for each woman (Gray et al,
2005) and categorised at the median value for analysis
(lowomedian, highXmedian).
The point prevalence of significant depression, significant
anxiety, distress, avoidance and intrusion was calculated at all
seven time points for (1) all women (i.e., combining trial arms) and
(2) by arm. The analysis combining trial arms was carried out to
assess the temporal trends in significant depression and anxiety.
The point prevalence of significant depression and significant
anxiety in all women was compared between consecutive time
points using z-tests. The analysis by arm compared the effects of
the management policies. Using data from the A3–A7 time points,
the cumulative prevalence of significant depression and anxiety in
each arm was computed (i.e., the percentage of women who scored
in the range for significant depression or significant anxiety at one
or more time point). Cumulative and point prevalence (i.e., at each
individual time point) was compared between arms using z-tests.
The Mann–Whitney/Wilcoxon test was used to compare total
POSM scores in all women from one time point to the next and
between arms at each time point. Logistic regression methods were
used to compute odds ratios (ORs) for immediate LLETZ vs biopsy
and selective recall. Separate models were built for each outcome.
Risk estimates were adjusted for the randomisation stratification
variables (adjusted ORs), and then for significant confounders
from among the socio-demographic, lifestyle and psychosocial
variables collected at recruitment and pre-colposcopy (multi-
variate ORs; candidate confounders are shown in Table 1).
Confounders were included in the multivariate models if they
were significant (Po0.1) on likelihood ratio tests. Final models
had adequate fit as assessed by the test of Hosmer and Lemeshow
(1989).
The analyses included only those women who completed all
questions on the relevant sub-scale/instrument. The number of
women excluded at each time point because of the missing items
was small (HADS: o5 in each arm; IES: o20 in each arm; POSM
o40 in each arm).
Sensitivity analyses were conducted to explore the impact on the
results of the cut-offs used to define ‘caseness’. The analyses
described above were repeated using alternative cut-offs. These
were: significant depression X11; significant anxiety X8; and
distress X25 and X44. To explore whether there was evidence of
participation bias, the primary analyses were repeated restricting
the study population to (1) women who had completed the
psychosocial questionnaire at every point from A3 to A7, and (2)
women who had completed the psychosocial questionnaire at only
one time point during A3 to A7.
Ethical approval
Ethical approval was obtained from the joint Research Ethics
Committee of NHS Grampian and the University of Aberdeen,
the Tayside Committee on Medical Research Ethics and the
Nottingham Research Ethics Committee. This approval required
that we inform the GP of any woman who scored X8 on the HADS
depression subscale at any time point.
RESULTS
Baseline characteristics of participants
In all, 989 women were eligible to take part, 487 of whom were
randomised to immediate LLETZ and 502 to biopsy and selective
recall (Figure 2). In all, 43% were aged 20–29, 27% aged 30–39,
21% aged 40–49 and 9% aged 50–59. Around one-quarter had
mild dyskaryosis at recruitment. The majority of women were
white and in full or part-time employment, and just over one-
quarter had obtained a college/university degree. Slightly more
than one-third were current smokers. One-third had never been
pregnant. The arms were balanced in terms of the randomisation
stratification variables (age group, recruitment cytology, centre
and high-risk HPV status), the socio-demographic and lifestyle
factors and psychosocial characteristics (MHLCS, EPQ) assessed at
recruitment (A1; Table 1), and prevalence of significant depression
(HADS subscale score X8) and significant anxiety (HADS
subscale score X11) and median POSM scores at recruitment
(Figures 3–5). At the pre-colposcopy psychosocial assessment
(A2), significant depression was more common in the biopsy and
recall arm (7.8 vs 4.1%), significant anxiety was more common in
the immediate LLETZ arm (16.2 vs 11.4%), and the median POSM
scores were identical (Figures 3–5).
Response rates
At recruitment and pre-colposcopy at least 97% of women in each
arm completed the psychosocial questionnaire (Figure 1). At
6 weeks post procedure (A3), the response rate was higher in the
immediate LLETZ arm (82 vs 72%; z¼3.73, Po0.01). Response
rates fell at subsequent time points (to between 57 and 74%), but
did not differ significantly between the arms at any point.
Psychosocial impact of management policies in women at colposcopy
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sHospital anxiety and depression scale: depression
Considering all women, the point prevalence of significant
depression was between 6.0 and 10.7% at each assessment point
from A1 to A7 (Figure 3), with no time point significantly different
from the successive one. On comparing management arms,
cumulative prevalence of significant depression over the entire
follow-up period was slightly lower in the immediate LLETZ arm
(16.7 vs 21.5%; Figure 3), and this was borderline statistically
significant (P¼0.067), but after adjustment for confounders risk
of depression did not differ significantly between arms (multi-
variate OR¼0.78, 95% CI 0.52–1.17). There were no differences
between the arms in point prevalence or risk of depression
at 6 weeks post procedure (A3) or at any subsequent time point
(A4–A7).
Hospital anxiety and depression scale: anxiety
Considering all women, point prevalence of significant anxiety
fell significantly from recruitment (A1: 22.3%) to pre-colposcopy
Table 1 Baseline characteristics of women included in analysis, by trial
arm; numbers and percentages
Immediate
LLETZ
Biopsy
and
recall
n % n %
Total 487 100.0 502 100.0
Clinical, socio-demographic and lifestyle factors
Age (years)
20–29 207 42.5 216 43.0
30–39 134 27.5 135 26.9
40–49 106 21.8 105 20.9
50–59 40 8.2 46 9.2
Recruitment cytology test
Mild dyskaryosis 117 24.0 121 24.1
Borderline nuclear abnormalities 370 76.0 381 75.9
Trial centre
A 177 36.3 189 37.7
B 119 24.4 121 24.1
C 191 39.2 192 38.3
Human papillomavirus status
a
Not high risk 257 52.8 255 50.8
High risk 174 35.7 189 37.7
Not known
b 56 11.5 58 11.6
Deprivation category
c
1 (least deprived) 57 11.7 70 13.9
2 77 15.8 110 21.9
3 101 20.7 69 13.8
4 147 30.2 127 25.3
5 (most deprived) 105 21.6 126 25.1
Post secondary school education/training
None 124 25.7 122 24.4
Through work with formal
qualifications
91 18.8 101 20.2
Qualifications other than degree
from college/university
137 28.4 142 28.5
University/college degree 131 27.1 134 26.9
Not stated 4 — 3 —
Employment status
Full-time paid employment 269 55.5 243 48.6
Part-time paid employment 105 21.7 123 24.6
Student 38 7.8 58 11.6
Not in paid employment 73 15.1 76 15.2
Not stated 2 — 2 —
Marital status
Married/living as married 258 53.5 267 53.7
Divorced/separated/widowed 70 14.5 60 12.1
Single 154 32.0 170 34.2
Not stated 5 — 5 —
Ethnicity
White 470 97.3 478 95.8
Other
d 13 2.7 21 4.2
Not stated 4 — 3 —
Parity
Never been pregnant 169 35.1 163 32.7
Have been pregnant, but no children 48 10.0 60 12.0
Have children 264 54.9 275 55.2
Not stated 6 — 4 —
Smoking status
Never smoked 240 49.7 230 46.2
Former smoker 71 14.7 91 18.3
Current smoker 172 35.6 177 35.5
Not stated 4 — 4 —
Physical activity
o1 Time/week 185 38.4 189 38.3
1–3 Times/week 114 23.7 111 22.5
43 Times/week 183 38.0 193 39.1
Not stated 5 — 9 —
Table 1 (Continued)
Immediate
LLETZ
Biopsy
and
recall
n % n %
Health locus of control
e
Chance
Lowest tertile (p16) 137 31.7 168 35.7
Middle tertile (17–21) 153 35.4 160 34.0
Highest tertile (X22) 142 32.9 142 30.2
Not completed
f 55 — 32 —
Internal
Lowest tertile (p25) 191 42.7 178 37.3
Middle tertile (26–28) 124 27.7 157 32.9
Highest tertile (X29) 132 29.5 142 29.8
Not completed
f 40 — 25 —
Powerful others
Lowest tertile (p14) 169 38.3 179 37.8
Middle tertile (15–19) 149 33.8 151 31.9
Highest tertile (X20) 123 27.9 144 30.4
Not completed
f 46 — 28 —
Personality
g
Neuroticism
Lowest tertile ( 6t o 2) 198 43.4 189 39.9
Middle tertile (0–2) 154 33.8 167 35.2
Highest tertile (4–6) 104 22.8 118 24.9
Not completed
f 31 — 28 —
Extraversion
Lowest tertile ( 6 to 2) 232 52.4 230 49.2
Middle tertile (4) 104 23.5 117 25.0
Highest tertile (6) 107 24.2 121 25.9
Not completed
f 44 — 34 —
aBased on PCR analysis with GP5+/6+ consensus primers, followed by enzyme
immunoassay for detection of 14 ‘high-risk’ human papillomavirus types.
bIncludes
women whose samples were inadequate for analysis, and women who did not have
human papillomavirus test.
cCarstairs deprivation measure based on population
quintiles assigned from address of residence at trial recruitment.
dOther ethnic group
includes Black-Caribbean (n¼13), Chinese (n¼5), Indian (n¼3), Black-British
(n¼2), Mixed race (n¼2), Mixed White and Indian (n¼2), Pakistani (n¼2) and
one each of Black-African, Japanese and Sri Lankan.
eAssessed by multi-dimensional
health locus of control scale, which measures three dimensions of health locus of
control (chance, internal and powerful others; Wallston et al, 1978).
fIncludes women
who either did not complete or only partially completed the questionnaire.
gAssessed
by Eysenck’s short questionnaire for the measurement of two dimensions of
personality: neuroticism–stability and extraversion–introversion (Eysenck, 1958).
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s2216 Randomised to initial colposcopy
2065 Attended for colposcopy 151 Did not have colposcopy
25 Did not consent to randomisation   2040 Consented to randomisation
1 Not randomised 2039 Randomised
55 Had inadequate colposcopy 1983 Had adequate colposcopy 1 Colposcopy not done
983 Allocated to immediate LLETZ 1000 Allocated to punch biopsies and selective recall
502 Recruited and attended
colposcopy after PS
questionnaires implemented
487 Recruited and attended
colposcopy after PS
questionnaires implemented
498 Recruited and attended
colposcopy before PS
questionnaires implemented
496 Recruited and attended
colposcopy before PS
questionnaires implemented
Number (%) who completed PS questionnaires
A1, baseline: 473 (97.1%)
A2, pre-colposcopy: 471 (96.7%)
A3, 6 weeks post procedure: 399 (81.9%)
A4, 12 months post recruitment: 360 (73.9%)
A5, 18 months post recruitment: 310 (63.7%)
A6, 24 months post recruitment: 312 (64.1%)
A7, 30 months post recruitment: 306 (62.8%)
Number (%) who completed PS questionnaires
A1, baseline: 493 (98.2%)
A2, pre-colposcopy: 488 (97.2%)
A3, 6 weeks post procedure: 361 (71.9%)
A4, 12 months post recruitment: 357 (71.1%)
A5, 18 months post recruitment: 333 (66.3%)
A6, 24 months post recruitment: 330 (65.7%)
A7, 30 months post recruitment: 288 (57.4%)
Figure 2 Numbers of women randomised and included in the psychosocial (PS) comparison.
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Recruitment (A1) Pre-colposcopy
(A2)
6 Weeks post
procedure (A3)
12 Months post
recruitment (A4)
18 Months post
recruitment (A5)
24 Months post
recruitment (A6)
30 Months post
recruitment (A7)
Cumulative1
All subjects 7.3% 6.0% 6.7% 7.9% 8.0% 10.7% 9.8%
By arm
16.7% 8.9% 9.9% 7.2% 7.6% 5.7% 4.1% 6.4% Immediate LLETZ
21.5% 10.7% 11.5% 11.6% 8.3% 7.9% 7.8% 8.2% Biopsy and recall
1.83, 0.067 –0.72, 0.473 –0.66, 0.512 –1.90, 0.057 –0.36, 0.722 –1.18, 0.239 –2.39, 0.017 –1.07, 0.286 z-score, P-value
Prevalence of significant depression
0.232 0.698 0.720 0.928 0.652 0.649 P-value4 – –
0.78 (0.52–1.17) 0.88 (0.45–1.70) 0.90 (0.49–1.63) 0.97 (0.49–1.91) 1.17 (0.59–2.33) 0.85 (0.41–1.74) Multivariate OR3, 95% CI – –
0.73 (0.52–1.02) 0.85 (0.49–1.47) 0.84 (0.50–1.41) 0.60 (0.34–1.05) 0.91 (0.52–1.58) 0.72 (0.40–1.30) – –
–
4
Odds ratios, immediate LLETZ vs biopsy and recall
Adjusted OR2, 95% CI
Figure 3 Prevalence of significant depression (HADS depression sub-scale score of X8), with odds ratios (ORs), 95% confidence intervals (CIs), and
P-values, by randomisation arm.
1Significant depression at any of the outcome assessment points, A3–A7.
2Adjusted for randomisation minimisation variables (age
group, trial centre, high-risk HPV status and recruitment cytology status).
3Adjusted for minimisation variables, and the following: 6 weeks, ever had children,
HADS depression pre-colposcopy, HADS anxiety pre-colposcopy, EPQ neuroticism, MHLCS chance; 12-months, ever had children, HADS depression pre-
colposcopy, HADS anxiety pre-colposcopy, EPQ neuroticism; 18 months, HADS depression pre-colposcopy, EPQ neuroticism smoking status; 24-months,e v e r
had children, HADS depression pre-colposcopy, HADS anxiety pre-colposcopy, EPQ neuroticism; 30 months, HADS depression pre-colposcopy, HADS anxiety
pre-colposcopy, smoking status; cumulative, HADS anxiety pre-colposcopy, HADS depression pre-colposcopy, EPQ neuroticism, smoking status, ever
had children, ethnic group, employment status.
4Likelihood ratio test P-value for randomisation arm, from multivariate model.
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s(A2: 13.8%; Po0.001; Figure 4) and from pre-colposcopy to 6 weeks
post procedure (A3: 8.0%; Po0.001), then returned to 13.8% at 12
months (A4: Po0.001) and remained stable thereafter. Cumulative
prevalence over the entire follow-up period did not differ between
arms (immediate LLETZ¼24.8%, biopsy and recall¼26.4%; multi-
variate OR¼0.83, 95% CI 0.57–1.19; Figure 4). There were no
significant differences in point prevalence or risk of anxiety between
the arms at any of the individual time points from A3 to A7.
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Recruitment (A1) Pre-colposcopy
(A2)
6 Weeks post
procedure (A3)
12 Months post
recruitment (A4)
18 Months post
recruitment (A5)
24 Months post
recruitment (A6)
30 Months post
recruitment (A7)
Cumulative1
0.55, 0.582
0.83 (0.57–1.19) 0.92 (0.53–1.60) 0.91 (0.50–1.65) 0.75 (0.43–1.31) 0.96 (0.53–1.75) 0.66 (0.33–1.30) – – Multivariate OR3, 95% Cl
0.91 (0.68–1.24) 1.02 (0.64–1.64) 0.98 (0.63–1.51) 0.72 (0.46–1.13) 1.00 (0.65–1.54) 0.70 (0.40–1.20) – – Adjusted OR2, 95% Cl
24.8% 14.1% 15.4% 12.4% 13.8% 6.8% 16.2% 22.6% Immediate LLETZ
26.4% 13.8% 15.8% 16.7% 13.8% 9.4% 11.4% 22.0% Biopsy and recall
0.11, 0.912 –0.01, 0.991 –1.52, 0.130 –0.17, 0.869 –1.27, 0.203 2.14, 0.033 0.23, 0.820
By arm
Odds ratios, immediate LLETZ vs biopsy and recall
Prevalence of significant anxiety
– – 0.904 0.229 0.759 0.303 0.309 0.763
All subjects 22.3% 13.8% 8.0% 13.8% 14.6% 15.6% 13.9% –
z-score, P-value
P-value4
Figure 4 Prevalence of significant anxiety (HADS depression sub-scale score of X11), with odds ratios (ORs), 95% confidence intervals (CIs), and
P-values, by randomisation arm.
1Significant anxiety at any of the outcome assessment points, A3–A7.
2Adjusted for randomisation minimisation variables
(age group, trial centre, high-risk HPV status and recruitment cytology status).
3Adjusted for minimisation variables, and the following: 6 weeks, ever had
children, HADS anxiety pre-colposcopy, EPQ neuroticism, MHLCS chance; 12-months, ever had children, deprivation category, HADS depression pre-
colposcopy, HADS anxiety pre-colposcopy, STAI pre-colposcopy, EPQ neuroticism; 18 months, HADS anxiety pre-colposcopy, HADS depression pre-
colposcopy, STAI pre-colposcopy, EPQ neuroticism; 24-months, smoking status, HADS depression pre-colposcopy, HADS anxiety pre-colposcopy, STAI
pre-colposcopy, EPQ neuroticism; 30 months, ever had children, HADS anxiety pre-colposcopy, EPQ neuroticism, MHLCS chance; cumulative, HADS
anxiety pre-colposcopy, HADS depression pre-colposcopy, EPQ neuroticism, ever had children, employment status.
4Likelihood ratio test P-value for
randomisation arm, from multivariate model.
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Figure 5 The POSM median scores, with P-values, by randomisation arm. IQR, interquartile range.
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sProcess outcome specific measure
In the entire group, the median POSM score fell significantly from
recruitment to 12 months (28 at A1 vs 25 at A4; Po0.001) and
between 12 and 18 months (24 at A5; Po0.001), and remained
stable thereafter. It did not differ significantly between arms at any
time point from 12 to 30 months (A4–A7; Figure 5).
Impact of event scale
There was no difference between arms in the point prevalence
of distress at 6 weeks post procedure (31.3 vs 31.5%; Table 2), or in
the distribution of distress scores. In the immediate LLETZ arm,
23.1% had mild distress (IES score 9–25); 5.0% had moderate
distress (26–43) and 3.2% severe distress (X44), compared with
22.8, 6.9 and 1.8% in the biopsy and recall arm (w
2(3df)¼2.38,
P¼0.498). There were no significant differences between arms in
the percentage, and risk of, scoring X20 on the avoidance or
intrusion subscales (Table 2).
Sensitivity analyses
Using different cut-offs to define caseness had no impact on the
overall findings (data not shown). When the analysis was repeated
by including only those women who had completed the (1) HADS
or (2) POSM at every outcome time point, the results were
unchanged (data not shown). Restricting the analysis to women
who had completed the (1) HADS or (2) POSM at a single outcome
time point did not affect the results (data not shown).
DISCUSSION
Strengths and limitations
The major strengths of this study include the randomised design
and the large size. In addition, the TOMBOLA trial was nested
within the United Kingdom Cervical Screening Programmes
that are population-based and free at the point of delivery. The
management policies evaluated were structured to mimic how they
would be delivered in clinical practice, and other than the
recruitment HPV test, no non-routine interventions were made
during the psychosocial follow-up. In all, 52% of eligible women
participated in TOMBOLA, which compares favourably with
population-based epidemiological studies (Olson, 2001), especially
in view of concerns about barriers to participation of women in
trials (Sharp et al, 2006). Participation was lower among younger
than older women (TOMBOLA Group, 2009b). As we have shown
that, among women with low-grade abnormal cervical cytology,
the prevalence of anxiety decreases with increasing age (Gray et al,
2006), our results may underestimate the overall frequency of
significant anxiety in this population. However, the internal
comparison of the management arms is entirely valid. In addition,
the ratio of BNA to mild cytology results at trial recruitment was
close to United Kingdom population figures (TOMBOLA Group,
2009a), and the incidence of CIN2 or worse over 3 years was
similar to other studies nested within the United Kingdom
screening programmes (Rana et al, 2004; Smith et al, 2006). This
suggests that generalisibility of the findings is likely to be high.
We assessed a range of psychosocial outcomes using well-
established and validated instruments (HADS and IES) with good
psychometric properties. The POSM was developed through an
extensive process, including literature review and focus groups,
and captures different sequelae than the HADS (Gray et al, 2005).
Unlike most of the previous studies, we also assessed the long-term
psychosocial outcomes of management, and carefully timed
assessments to avoid being unduly influenced by short-term
affects of attending for follow-up tests or receipt of results.
It is possible that women’s knowledge and understanding of
abnormal cervical cytology results and cervical cancer at recruit-
ment might have influenced the psychosocial impact of the
management options following colposcopy, but randomisation
should have balanced these factors between the arms. As the trial
was pragmatic in design, we did not standardise the information
that women were given by the health professionals involved
in their care (other than the information leaflets provided at
recruitment and before the randomisation). It is likely that there
was considerable heterogeneity in the amount and content of the
information women sought and obtained during trial participa-
tion, both from health professionals and other sources (e.g., the
internet), and their understanding of this information. However,
all of the trial colposcopists treated women in both arms, and it
would be expected that the health- and information-seeking
behaviour of women in the two arms would be similar. Therefore,
we do not expect these factors to have strongly affected the
comparison of the management policies.
Questionnaire response rates were highest at the 6-week assess-
ment (A3) and decreased over time. Our analysis of individual
time points included women who responded at that time point.
Other than at the 6-week assessment, response rates did not differ
by arm at any time point. The socio-demographic characteristics of
responders at each point were similar to those of the entire study
population. We examined the possibility that non-responders were
women who scored high (or low) on a particular sub-scale/
instrument. Slightly lower proportions of women who scored in the
range for clinically significant depression or anxiety at recruitment
completed all five of the outcome questionnaires (percentage
completing all questionnaires for women with depression scores
X8, 38% compared with 43% for women with lower depression
scores; for anxiety X11, 38% compared with 44%,), but these
differences were not statistically significant. Nor was there any
significant association between the number of outcome question-
naires completed (i.e., 0–5) by depression or anxiety level at
recruitment. Moreover, there were no significant differences in these
associations between the trial arms. In addition, our sensitivity
analysis showed that the results were unchanged if the analysis
was restricted to women who had completed questionnaires at only
one, or at every, time point during A3–A7.
Table 2 Distress, avoidance and intrusion at 6 weeks post
procedure (A3): prevalence, z-scores, odds ratios, 95% confidence intervals
and P-values
Distress
a Avoidance
b Intrusion
c
Prevalence
Immediate LLETZ 31.3% 6.0% 2.6%
Biopsy and recall 31.5% 7.3% 1.8%
z-score, P-value  0.07, 0.947  0.70, 0.486 0.77, 0.442
Odds ratios, immediate LLETZ vs biopsy and recall
Adjusted OR,
95% CI
d
0.97 (0.70–1.34) 0.79 (0.44–1.43) 1.48 (0.53–4.16)
Multivariate OR,
95% CI
e
0.97 (0.68–1.37) 0.81 (0.40–1.63) 1.51 (0.48–4.77)
P-value
f 0.848 0.557 0.478
Abbreviations: CI¼confidence interval; EPQ¼Eysenck personality questionnaire;
HADS¼hospital anxiety and depression scale; HPV¼human papillomavirus;
IES¼impact of event scale; MHLCS¼multi-dimensional health locus of control
scale; OR¼odds ratio.
aPercentage scoring X9 on the IES.
bPercentage scoring X20
on the IES avoidance subscale.
cPercentage scoring X20 on the IES intrusion
subscale.
dAdjusted for randomisation minimisation variables (age group, trial centre,
high-risk HPV status and recruitment cytology status).
eAdjusted for minimisation
variables, and the following: distress, HADS anxiety pre-colposcopy; avoidance,
HADS anxiety pre-colposcopy, EPQ neuroticism, EPQ extraversion, MHLCS
powerful others, ethnic group; intrusion, HADS anxiety pre-colposcopy, HADS
depression pre-colposcopy.
fLikelihood ratio test P-value for randomisation arm, from
multivariate model.
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This is the first randomised controlled trial comparing psychoso-
cial outcomes in women with low-grade abnormal cervical
cytology attending colposcopy and managed by different app-
roaches. The lack of any differences between the trial arms in
significant depression or significant anxiety leads us to conclude
that the short- and long-term psychosocial effects of immediate
LLETZ and biopsy and selective recall do not differ. This
conclusion is further reinforced by our observation of no
difference between arms in the scores of women on the POSM,
an instrument designed specifically to measure psychosocial
outcomes associated with low-grade abnormal cervical cytology
results and their management (Gray et al, 2005).
The only other study to investigate the psychosocial impact of
alternative management strategies included 272 women with a
colposcopic impression of high-grade disease (Orbell et al, 2004;
Balasubramani et al, 2007). That study found that, 7 days after
colposcopy, anxiety was significantly higher and relief significantly
lower, among women undergoing biopsy and recall than among
women who had had LLETZ at the colposcopy visit. Although not
randomised, in an attempt to minimise bias, the authors matched
women undergoing biopsy and recall to those who had LLETZ on
severity of abnormality, age and deprivation of area of residence.
However, our observation that prevalence of significant depression
and anxiety pre-colposcopy differed between the trial arms serves
to illustrate how intervention groups can differ in important ways
even using a study design which strongly protects against bias,
such as a randomised controlled trial. Fortunately, because we had
measured depression and anxiety pre-colposcopy, we were able to
adjust our analysis appropriately. The contrasting findings of our
study and Balasubramani et al (2007) might also be a function of
differences in the psychosocial instruments used and, importantly,
the timing of assessment. Balasubramani et al (2007) dispatched
their questionnaire within 7 days of colposcopy. At this point, it is
likely that most women being managed by biopsy and recall would
not have received their biopsy results and so would not have had
any treatment: women in the biopsy group were, thus, in the midst
of investigation and treatment, whereas those who had had LLETZ
at the colposcopy visit had completed treatment. In contrast, we
designed our short-term assessment so it would take place after
treatment was completed in both arms (i.e., 6 weeks after the last
intervention).
Temporal trajectory of depression and anxiety
This study reveals the temporal trajectory of depression in women
with low-grade abnormal cervical cytology attending colposcopy.
The point prevalence of significant depression (HADS depression
score X8) rose from 6–7% at recruitment and pre-colposcopy to
10–11% at 24 and 30 months. This difference is statistically
significant on a post hoc test. We informed GPs of those women
who scored X8 at any time point; hence, over time, some women
(we do not know how many because of doctor–patient con-
fidentiality) may have been treated for depression, which may have
reduced the underlying prevalence. In light of this, the observed
rise is intriguing and might suggest that the extended follow-up
after colposcopy and treatment (mainly by 6-monthly cervical
cytology tests until a woman has three consecutive normal tests
and is returned to routine 3- or 5-yearly recall) is associated with
depression for a small proportion of women. Longitudinal studies
of women on long-term follow-up would be needed to further
unravel this issue.
The long-term frequency of significant depression in our study
was lower than in general population series in Denmark
(604 women aged 30–75 years; 12% scored X8), the United
Kingdom (978 women aged 18–91 years; 13% scored X8), and the
Netherlands (2048 women aged 18–65 years; 22% scored X8;
Groenvold et al, 1999; Crawford et al, 2001; Andrea et al, 2004). In
addition, in a study of 100 women undergoing colposcopy, there
was little change in average depression scores between the initial
visit and at 6 months and 2 years later (Hellsten et al, 2008). These
observations suggest that receipt of an abnormal cervical cytology
result, attendance for colposcopy and subsequent management
does not have a strong influence on prevalence of clinically
significant depression, either because these events do not
themselves impact on depression, or because the information
women receive (or source themselves) effectively counters adverse
psychosocial effects.
The temporal pattern of anxiety was different to that for
depression. Almost one-quarter of women had significant anxiety
(HADS anxiety score X11) at trial recruitment, shortly after
receipt of the low-grade result, falling significantly to 14% at the
colposcopy appointment around 4–12 weeks later, and to 8% 6
weeks after the last procedure. As anxiety is often triggered
by uncertainty and anticipation of unknown adverse outcomes
(Craig et al, 2000), this pattern is what one might expect a priori as
the uncertainty associated with receipt of the cytology result
‘resolves’ with investigation and treatment. Two further conclu-
sions follow from our data. First, our finding of no significant
difference in anxiety 6 weeks post procedure between the
management arms suggests that, for most women, undergoing
colposcopic investigation and, perhaps also, treatment – irrespec-
tive of the procedure(s) received – alleviates, to some extent, the
raised anxiety induced by receipt of the cytology result. Second,
there is a significant rise in the anxiety levels after colposcopy and
treatment, from 8% at 6 weeks post procedure to 14% at 12
months, with prevalence remaining stable thereafter. This long-
term prevalence is similar to values reported in the European
studies described above (UK, 15%; Denmark, 12%; Netherlands,
10%) (Groenvold et al, 1999; Crawford et al, 2001; Andrea et al,
2004). These two observations suggest that the apparent ‘resolu-
tion’ in anxiety after colposcopy is temporary, and an artefact
of having undergone investigation and treatment, but that in the
long-term prevalence returns to background levels.
Short-term psychological distress following colposcopy
and treatment compared with other interventions
Although the IES has been used fairly frequently to assess distress
among cancer survivors (see, e.g., Kelly et al, 1995; Chen et al,
2005; Shim et al, 2006), it has rarely been applied in the context of
screening or investigations for suspected cancer. The average
distress score and the percentage with moderate or severe distress
at 6 weeks post procedure in our study (mean¼8.0, median¼3.0;
score X26¼8%) were higher than those measured at 1 week post
endoscopy in a group of 192 individuals with Barrett’s oesophagus
(mean B3.5; X26¼6%; Kruijshaar et al, 2006). Our participants
also had higher distress scores than 236 individuals who
had undergone lung cancer screening 6 months previously and
had considered themselves, pre-screening, to have low cancer risk
(mean¼4.3, median¼1.0; Bunge et al, 2008). Studies are difficult
to compare because of the differences in participants’ gender and
age and the timing of assessment of distress. However, it is
possible to conclude that colposcopy and related interventions
(irrespective of whether these are punch biopsies or loop excision)
seem to provoke significant distress for a notable proportion of
women, an important consideration to bear in mind when
assessing the costs and benefits of cervical screening.
Conclusions
See-and-treat has become increasingly common in the manage-
ment of women with low-grade cytology in the United Kingdom
(Kitchener et al, 1995). We have previously shown that immediate
LLETZ and punch biopsies with selective recall do not differ in
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stheir ability to detect CIN2 or worse over 3 years (TOMBOLA
Group, 2009a), or in their cost effectiveness (TOMBOLA Group,
2009c). See-and-treat results in more women undergoing unne-
cessary treatment and experiencing physical aftereffects, such
as pain and bleeding (TOMBOLA Group, 2009b,d). Others have
found that LLETZ is associated with subsequent adverse repro-
ductive outcomes (Noehr et al, 2009). This study shows that there
is no difference in long- or short-term psychosocial sequelae of the
two approaches. Debate as to which strategy offers the best balance
between benefits and harms in women with low-grade abnormal
cytology referred for colposcopy is likely to continue.
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